News

Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.

After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.

This decision may lead to faster approval of new treatments for multiple myeloma.

The executive order was created to acknowledge the challenges faced by families in accessing affordable, high-quality care, mainly due to the gap between costs and what families can afford.

Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.

One result of the Inflation Reduction Act shifting a greater proportion the cost of drugs during the catastrophic phase of coverage to the Part D plans result may be narrower formularies.

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers (PBMs) and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy (AMCP) today.

Psychiatrists and psychologists also had lower in-network reimbursement rates.

Panelists discussed reaching beyond large patient advocacy groups for input and how clinical trial endpoints may paint an incomplete picture of a drug's true value to patients.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses whether proposed transparency rules in the pharmacy benefit manager (PBM) legislation that Congress is considering might apply to the PBM-affiliated group purchasing organizations.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses proposals to “delink” what pharmacy benefit managers are paid from the price of drugs.

The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to think about coverage issues.

According to the co-author of a poster presented at the annual AMCP meeting hosted in New Orleans this week, the interest in the study where the data was found stemmed from the prevalence of PPD in adults, especially women after giving birth.

Factors preventing biosimilar access include pharmacy benefit manager contracts and pharmacies not communicating with providers, a survey finds.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, says there is broad agreement on transparency provisions and a ban on spread pricing in Medicaid.

The Access to Prescription Digital Therapeutics Act remains a top priority for the Academy of Managed Care Pharmacy (AMCP), according to Jennifer L. Mathieu, AMCP senior vice president of professional and government affairs.

Generation Z (1997–2012). Everything on demand, including healthcare

CEO John Baackes is stepping down at the end of this year.

In a slow week, the FDA has approved Fasenra for children 6 to 11 years of age with eosinophilic asthma, a rare form of asthma.

On specialty drugs, the Prime acquisition and vertical integration

Gen X (1965–1980), still traditional — and stuck in the middle.

The need for tools that effectively route patients to the right care at the right time has intensified. But relying only on a tech-enabled approach heightens the potential for missed human connections.

The proposed rule for the fiscal year (FY) 2025 Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System introduces strategies to improve the well-being of Medicare beneficiaries, including efforts to tackle social determinants of health, create more robust emergency readiness and enhance maternal healthcare.

The average American can afford a maximum of a $97 for out-of-pocket healthcare expenses.

Ten biosimilars to Humira are now on the market, but AbbVie’s Skyrizi and Rinvoq are soaking up revenues as Humira’s sales fall off.

How COVID-19 became a jumping off point for HIV vaccine conspiracies.

If the company' experimental agent is approved, it would join Humira (adalimumab), Rinvoq (upadacitinib) and Skyrizi (risankizumab) in AbbVie's portfolio.